In conclusion, our findings support novel therapeutic possibilities for a wide-spectrum of CIP2A/AKT-inhibiting drugs such asFTY720 in breast cancer to be used alone or in combination with standard anthracycline-based chemotherapy. The gene discussed is AKT1; the disease is breast cancer.